- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05974137
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
August 2, 2023 updated by: Carevive Systems, Inc.
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML). Using Remote Symptom Monitoring
To create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
25
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Canton, Ohio, United States, 44708
- Recruiting
- Cleveland Clinic Mercy Hospital
-
Principal Investigator:
- Mitchell Haut, MD
-
Contact:
- Janet Muckley
- Phone Number: 330-453-9993
- Email: MUCKLEJ@ccf.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
patients receiving cancer treatment for breast, lung, AML, or multiple myeloma
Description
Inclusion Criteria:
- All participants must be 18 years of age or older.
- Subjects may be any stage and anywhere in the treatment continuum.
- Subject participants must have a diagnosis of a breast, lung, AML,ovarian cancer or multiple myeloma.
- Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
- All participants must be able to understand English.
Exclusion Criteria:
- Any patient who cannot understand written or spoken English
- Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer
- Any patient on a treatment clinical trial
- Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Data Set creation
Time Frame: 1 year
|
The goal of this registry is to create a data set from real world clinical and patient reported data collected using an electronic care planning system (CPS) that is used in routine care for cancer patients on active treatment
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 21, 2023
Primary Completion (Estimated)
July 5, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
July 26, 2023
First Submitted That Met QC Criteria
August 2, 2023
First Posted (Actual)
August 3, 2023
Study Record Updates
Last Update Posted (Actual)
August 3, 2023
Last Update Submitted That Met QC Criteria
August 2, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
Other Study ID Numbers
- OPT-IN Mercy Registry
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Web bases survey
-
Unita Complessa di Ostetricia e GinecologiaCompletedCOVID-19 | Coronavirus Infection | COVID | Coronavirus | Transgender PersonsItaly
-
University of South FloridaUniversity of Miami; National Institutes of Health (NIH); University of KansasCompletedAmyotrophic Lateral Sclerosis | Primary Lateral Sclerosis | Progressive Muscular Atrophy | Hereditary Spastic Paraplegia
-
University of South FloridaUniversity of Miami; University of Alabama at Birmingham; Icahn School of Medicine... and other collaboratorsCompletedPorphyriasUnited States
-
University of South FloridaNational Institutes of Health (NIH); Rare Diseases Clinical Research NetworkCompletedOsteogenesis Imperfecta | Brittle Bone DisordersUnited States
-
University of South FloridaNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsCompletedCarpal Tunnel Syndrome | Charcot-Marie-Tooth Disease | Inherited Peripheral NeuropathyUnited States
-
University of South FloridaNational Institutes of Health (NIH); Rare Diseases Clinical Research NetworkCompletedOsteogenesis Imperfecta | Brittle Bone DisordersUnited States
-
Carevive Systems, Inc.RecruitingBreast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Acute Myelogenous LeukemiaUnited States
-
University Hospital, CaenINSERM UMR U1075 Comète GIP Cyceron, unicaen, Caen NormandieRecruiting
-
D'Or Institute for Research and EducationConselho Nacional de Desenvolvimento Científico e TecnológicoActive, not recruitingDepression | Covid19 | Burnout, Professional | Stress Disorders, Post-Traumatic | Compassion Fatigue | AnxietyBrazil
-
Assiut UniversityCompletedCOVID-19 | Sleep Quality | General HealthEgypt